Recognition of DNA modified by trans-[PtCl2NH 3(4-hydroxymethylpyridine)] by tumor suppressor protein p53 and character of DNA adducts of this cytotoxic complex

FEBS Journal

Volumn 273, Issue 2, 2006, Pages 301-314

  Stehlíková, Kristýna ^a   Kašpárková, Jana ^a   Nováková, Olga ^a   Martínez, Alberto ^b   Moreno, Virtudes ^b   Brabec, Viktor ^a  

^a INSTITUTE OF BIOPHYSICS   (Czech Republic)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antitumor; Conformation; DNA; p53; Platinum drug

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOUBLE STRANDED DNA; PICOLINE DERIVATIVE; PLATINUM DERIVATIVE; PROTEIN P53; TRANSPLATIN;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CYTOTOXICITY; DNA ADDUCT; DNA CONFORMATION; DNA CROSS LINKING; DNA DENATURATION; DNA MODIFICATION; DRUG BINDING SITE; DRUG DNA BINDING; DRUG EFFECT; DRUG MECHANISM; PRIORITY JOURNAL; PROTEIN DNA BINDING; TRANS ISOMER;

ANIMALS; BASE SEQUENCE; CATTLE; CIRCULAR DICHROISM; DNA; DNA ADDUCTS; OLIGONUCLEOTIDES; ORGANOPLATINUM COMPOUNDS; PROTEIN BINDING; PYRIDINES; SPECTROPHOTOMETRY, ATOMIC; SPECTROPHOTOMETRY, ULTRAVIOLET; THIOUREA; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33645037498     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2005.05061.x     Document Type: Article

References (57)

1. Farrell N 1996 Current status of structure-activity relationships of platinum anticancer drugs: Activation of the trans geometry. In Metal Ions in Biological Systems Sigel A Sigel H, eds), Vol. 32, pp. 603 639 Marcel Dekker, Inc. New York, Basel, Hong Kong
2. Perez J-M Fuertes MA Alonso C Navarro-Ranninger C 2000 Current status of the development of trans-platinum antitumor drugs Crit Rev Oncol Hematol 35 109 120
3. Brabec V 2002 DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair Prog Nucleic Acid Res Mol Biol 71 1 68
4. Natile G Coluccia M 2004 Antitumor active trans-platinum compounds. In Metal Ions in Biological Systems Sigel A Sigel H, eds), Vol. 42, pp. 209 250 Marcel Dekker, Inc. New York, Basel
5. 3 (4-(hydroxymethyl)-pyridine) Polyhedron 22 3379 3381
6. Martinez A Lorenzo J Prieto MJ de Llorens R Font-Bardia M Solans X Aviles FX Moreno V 2005 Synthesis, characterization and biological activity of trans-platinum(II) and trans-platinum(IV) compounds with 4-hydroxymethylpyridine Chembiochem 6 2068 2077
7. Brabec V Kasparkova J 2002 Molecular aspects of resistance to antitumor platinum drugs Drug Resist Updates 5 147 161
8. Siddik ZH 2003 Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 7265 7279
9. Fuertes MA Castilla J Alonso C Perez JM 2003 Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways Curr Med Chem 10 257 266
10. Jordan P Carmo-Fonseca M 2000 Molecular mechanisms involved in cisplatin cytotoxicity Cell Mol Life Sci 57 1229 1235
11. Clarke PA Pestell KE Di Stefano F Workman P Walton MI 2004 Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo Br J Cancer 91 1614 1623
12. Janus F Albrechtsen N Dornreiter I Wiesmüller L Grosse F Deppert W 1999 The dual role model for p53 in maintaining genomic integrity Cell Mol Life Sci 55 12 27
13. Kasparkova J Pospisilova S Brabec V 2001 Different recognition of DNA modified by antitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53 J Biol Chem 276 16064 16069
14. Kasparkova J Fojta M Farrell N Brabec V 2004 Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin Nucleic Acids Res 32 5546 5552
15. El-Deiry WS Kern SE Pietenpol JA Kinzler KW Vogelstein B 1992 Definition of a consensus binding site for p53 Nature Genet 1 45 49
16. Mazur SJ Sakaguchi K Appella E Wang XW Harris CC Bohr VA 1999 Preferential binding of tumor suppressor p53 to positively or negatively supercoiled DNA involves the C-terminal domain J Mol Biol 292 241 249
17. Fojta M Pivonkova H Brazdova M Kovarova L Palecek E Pospisilova S Vojtesek B Kasparkova J Brabec V 2003 Recognition of DNA modified by antitumor cisplatin by 'latent' and 'active' protein p53 Biochem Pharmacol 65 1305 1316
18. Bancroft DP Lepre CA Lippard SJ 1990 Part-195 NMR kinetic and mechanistic studies of cis-diamminedichloroplatinum and trans-diamminedichloroplatinum(II) binding to DNA J Am Chem Soc 112 6860 6871
19. Murray V 2000 A survey of the sequence-specific interaction of damaging agents with DNA: emphasis on antitumor agents Prog Nucleic Acid Res Mol Biol 63 367 415
20. Axelrod VD Kramer FR 1985 Transcription from bacteriophage T7 and SP6 RNA polymerase promoters in the presence of 3′-deoxyribonucleoside 5′-triphosphate chain terminators Biochemistry 24 5716 5723
21. Lemaire MA Schwartz A Rahmouni AR Leng M 1991 Interstrand cross-links are preferentially formed at the d (GC) sites in the reaction between cis-diamminedichloroplatinum (II) and DNA Proc Natl Acad Sci USA 88 1982 1985
22. Brabec V Leng M 1993 DNA interstrand cross-links of trans- diamminedichloroplatinum(II) are preferentially formed between guanine and complementary cytosine residues Proc Natl Acad Sci USA 90 5345 5349
23. Cullinane C Wickham G McFadyen W Denny W Palmer B Phillips D 1993 The use of bidirectional transcription footprinting to detect platinum-DNA crosslinks by acridine-tethered platinum diamine complexes and cisplatin Nucleic Acids Res 21 393 400
24. Puvvada MS Forrow SA Hartley JA Stephenson P Gibson I Jenkins TC Thurston DE 1997 Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1-c][1,4]benzodiazepines Biochemistry 36 2478 2484
25. Sasaki N Izawa M Watahiki M Ozawa K Tanaka T Yoneda Y Matsuura S Carninci P Muramatsu M Okazaki Y et al. 1998 Transcriptional sequencing: a method for DNA sequencing using RNA polymerase Proc Natl Acad Sci USA 95 3455 3460
26. Perrin LC Cullinane C McFadyen WD Phillips DR 1999 Sequence specificity and reactivity of the binding of phenazine-tethered platinum complexes to DNA Anticancer Drug Design 14 243 252
27. Kalogeraki VS Tornaletti S Hanawalt PC 2003 Transcription arrest at a lesion in the transcribed DNA strand in vitro is not affected by a nearby lesion in the opposite strand J Biol Chem 278 19558 19564
28. Corda Y Job C Anin MF Leng M Job D 1991 Transcription by eucaryotic and procaryotic RNA polymerases of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis-diamminedichloroplatinum(II) Biochemistry 30 222 230
29. Cullinane C Mazur SJ Essigmann JM Phillips DR Bohr VA 1999 Inhibition of RNA polymerase II transcription in human cell extracts by cisplatin DNA damage Biochemistry 38 6204 6212
30. Eastman A 1987 The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes Pharmacol Ther 34 155 166
31. Fichtinger-Schepman AMJ Van der Veer JL Den Hartog JHJ Lohman PHM Reedijk J 1985 Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation Biochemistry 24 707 713
32. Eastman A Barry MA 1987 Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione Biochemistry 26 3303 3307
33. 2] Nucleic Acids Res 24 336 341
34. Kasparkova J Marini V Najajreh Y Gibson D Brabec V 2003 DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines Biochemistry 42 6321 6332
35. Boudvillain M Dalbies R Aussourd C Leng M 1995 Intrastrand cross-links are not formed in the reaction between transplatin and native DNA: relation with the clinical inefficiency of transplatin Nucleic Acids Res 23 2381 2388
36. Keck MV Lippard SJ 1992 Unwinding of supercoiled DNA by platinum ethidium and related complexes J Am Chem Soc 114 3386 3390
37. Zaludova R Kleinwächter V Brabec V 1996 The effect of ionic strength on melting of DNA modified by platinum(II) complexes Biophys Chem 60 135 142
38. Brabec V Kleinwächter V Butour JL Johnson NP 1990 Biophysical studies of the modification of DNA by antitumour platinum coordination complexes Biophys Chem 35 129 141
39. Brabec V Neplechova K Kasparkova J Farrell N 2000 Steric control of DNA interstrand cross-link sites of trans platinum complexes: specificity can be dictated by planar nonleaving groups J Biol Inorg Chem 5 364 368
40. 3)(quinoline) ] Eur J Biochem 254 547 557
41. 3)(thiazole)]: protein recognition and nucleotide excision repair of monofunctional adducts Biochemistry 42 792 800
42. Kasparkova J Novakova O Marini V Najajreh Y Gibson D Perez J-M Brabec V 2003 Activation of trans geometry in bifunctional mononuclear platinum complexes by a piperidine ligand: mechanistic studies on antitumor action J Biol Chem 278 47516 47525
43. Prokop R Kasparkova J Novakova O Marini V Pizarro AM Navarro-Ranninger C Brabec V 2004 DNA interactions of new antitumor platinum complexes with trans geometry activated by a 2-metylbutylamine or sec-butylamine ligand Biochem Pharmacol 67 1097 1109
44. 2]: a concept for activation of the trans geometry in platinum antitumor complexes Nucleic Acids Res 31 6450 6460
45. Vrana O Brabec V Kleinwächter V 1986 Polarographic studies on the conformation of some platinum complexes: relations to anti-tumour activity Anti-Cancer Drug Design 1 95 109
46. Farrell N Qu Y Hacker MP 1990 Cytotoxicity and antitumor activity of bis (platinum) complexes - a novel class of platinum complexes active in cell lines resistant to both cisplatin and 1,2-diaminocyclohexane complexes J Med Chem 33 2179 2184
47. Nagaich AK Zhurkin VB Durell SR Jernigan RL Appella E Harrington RE 1999 p53-induced DNA bending and twisting: p53 tetramer binds on the outer side of a DNA loop and increases DNA twisting Proc Natl Acad Sci USA 96 1875 1880
48. Brabec V Sip M Leng M 1993 DNA conformational distortion produced by site-specific interstrand cross-link of trans-diamminedichloroplatinum(II) Biochemistry 32 11676 11681
49. Hofr C Brabec V 2005 Thermal stability and energetics of 15-mer DNA duplex interstrand cross-linked by trans-diamminedichloroplatinum(II) Biopolymers 77 222 229
50. Brabec V Palecek E 1976 Interaction of nucleic acids with electrically charged surfaces. II. Conformational changes in double-helical polynucleotides Biophys Chem 4 76 92
51. Brabec V Reedijk J Leng M 1992 Sequence-dependent distortions induced in DNA by monofunctional platinum(II) binding Biochemistry 31 12397 12402
52. Kasparkova J Farrell N Brabec V 2000 Sequence specificity, conformation, and recognition by HMG1 protein of major DNA interstrand cross-links of antitumor dinuclear platinum complexes J Biol Chem 275 15789 15798
53. Hupp TR Lane DP 1995 Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner J Biol Chem 270 18165 18174
54. Kim SD Vrana O Kleinwächter V Niki K Brabec V 1990 Polarographic determination of subnanogram quantities of free platinum in reaction mixture with DNA Anal Lett 23 1505 1518
55. Kasparkova J Mellish KJ Qu Y Brabec V Farrell N 1996 Site-specific d(GpG) intrastrand cross-links formed by dinuclear platinum complexes: bending and NMR studies Biochemistry 35 16705 16713
56. Vojtesek B Bartek J Midgley CA Lane DP 1992 An immunochemical analysis of the human nuclear phosphoprotein p53 - new monoclonal-antibodies and epitope mapping using recombinant p53 J Immunol Methods 151 237 244
57. Farrell N Qu Y Feng L Van Houten B 1990 Comparison of chemical reactivity, cytotoxicity, interstrand cross-linking and DNA sequence specificity of bis(platinum) complexes containing monodentate or bidentate coordination spheres with their monomeric analogues Biochemistry 29 9522 9531